On Wednesday, World Health Organisation (WHO) said it expects to receive clarifications from Bharat Biotech by the end of this week on its COVID-19 vaccine, Covaxin and will meet on November 3 for a final risk-benefit assessment for the Emergency Use Listing.

• Hatsun Agro Shares Gained 14% on Robust Q4FY24 Business and Financial Updates
• Mahindra Logistics Shares Gain 2% on Q4 Earning Result
• Tejas Networks Stocks Skyrocketed 20% on Strong Q4FY24 Business and Financial Performance
• PSP Project Shares Surge 4% on Launching Rs 244 Crore QIP
• Stocks in Focus: Adani Group, Patel Engineering, Reliance Industries, Inox Wind, and Others

WHO Technical Advisory Group for Emergency Use Listing (EUL) is an independent advisory group that provides recommendations to WHO on whether a #COVID19 vaccine can be listed for emergency use under the EUL procedure, the WHO tweeted.

The Technical Advisory Group met on October 26 and decided that additional clarifications from the manufacturer (Bharat Biotech) are needed to conduct a final EUL risk-benefit assessment for global use of the Covaxin vaccine”.

The Technical Advisory Group expects to receive these clarifications from the manufacturer (Bharat Biotech) by the end of this week. It aims to reconvene for the final risk-benefit assessment on Wednesday, November 3, 2021, the WHO tweeted.